News articles about NxStage Medical (NASDAQ:NXTM) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 47.2174719027211 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of NxStage Medical stock opened at $24.53 on Friday. The stock has a market cap of $1,626.85, a price-to-earnings ratio of -350.43 and a beta of 0.02. NxStage Medical has a 1 year low of $20.45 and a 1 year high of $30.80.
Several equities analysts have commented on the stock. Zacks Investment Research cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, February 13th. BidaskClub cut shares of NxStage Medical from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 15th. Finally, ValuEngine cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Three equities research analysts have rated the stock with a sell rating and eight have given a hold rating to the stock. The company currently has an average rating of “Hold” and an average price target of $30.25.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.